Hypercholesterolaemia Clinical Trial
Official title:
Study of Bioequivalence Between Two Formulations of 20 mg Rosuvastatin Calcium Tablets, Administered Under Fasting to Healthy Volunteers of Both Genders, Being the Test Formulation Manufactured by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda. and the Reference Formulation (Crestor®) Commercialized by AstraZeneca do Brasil Ltda.
This is an open-label, randomized, two treatment, two sequences, two periods crossover study, using a crossover 2x2 design, where each subject will be randomly assigned to reference or test formulation, in order to evaluate if both formulations are bioequivalent.
The objective of this study is to confirm if two formulations of rosuvastatin calcium 20 mg tablets are bioequivalent. Test formulation is rosuvastatin calcium 20 mg tablets - manufactured by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brazil Ltda., administration of one single-dose tablet. Reference formulation is rosuvastatin calcium 20 mg tablets (Crestor® 20 mg - AstraZeneca do Brasil Ltda.), administration of one single-dose tablet. Sixty-four healthy volunteers, of both genders, with age ranging from 18 and 50 years old, will receive test or reference formulation under fasting conditions, according to the randomization list. In each period, after administration of medication, blood samples are collected at the following times: 0:00 (prior to administration), 0:30, 1:00, 1:30, 2:00, 2:20, 2:40: 3:00, 3:20, 3:40, 4:00, 4:20, 4:40, 5:00, 5:30, 6:00, 7:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 and 72:00 hours. The comparative bioavailability of formulations is evaluated based on relevant pharmacokinetic parameters for statistical comparison. Such parameters are obtained directly from the determination of the drug active principle plasmatic concentration, based on the application of a non-compartmental pattern for the evaluation of these concentrations after the drug oral administration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01935674 -
Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
|
Phase 4 | |
| Completed |
NCT02890992 -
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
|
Phase 2 | |
| Completed |
NCT00653835 -
Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)
|
Phase 4 | |
| Recruiting |
NCT06008756 -
MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
|
Phase 3 | |
| Completed |
NCT02585778 -
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
|
Phase 3 | |
| Completed |
NCT00329173 -
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
|
Phase 3 | |
| Completed |
NCT04169386 -
A Study of PCSK9 Inhibitor AK102 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02770131 -
Chart Review of Repatha® in Subjects With Hyperlipidaemia
|
||
| Completed |
NCT03510884 -
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Recruiting |
NCT06275724 -
Specified Drug-use Survey of Leqvio for s.c. Injection.
|
||
| Completed |
NCT03415178 -
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
|
Phase 3 | |
| Completed |
NCT01779687 -
Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.
|
Phase 1 | |
| Completed |
NCT01617655 -
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
|
Phase 3 | |
| Completed |
NCT00328523 -
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
|
Phase 3 | |
| Completed |
NCT05934292 -
MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)
|
Phase 1 | |
| Completed |
NCT01257971 -
Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors
|
N/A | |
| Completed |
NCT00163163 -
Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women
|
Phase 3 | |
| Completed |
NCT01597700 -
Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.
|
Phase 1 | |
| Terminated |
NCT02906124 -
Study to Evaluate the Safety of Repatha® in Pregnancy
|
||
| Completed |
NCT02065180 -
The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol Levels in Patients With Metabolic Syndrome
|
Phase 4 |